Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK5764227 in previously treated advanced colorectal cancer and pancreatic cancer
NL-OMON59679Phase 2Recruiting
- Sponsor
- GSK
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of risvutatug rezetecan in colorectal cancer (CRC) and pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by GSK. Primary endpoint: Confirmed objective response rate. Started Sep 2025; status: recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
colorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON59679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59679.